Source: Prensa Latina
Havana, (Prensa Latina) A group of Russian companies, enterprises of the Skolkovo Foundation, and Heber Biotec of Cuba, signed today four agreements to strengthen strategic cooperation in the biomedical field. The companies R-Pharm, the Stem Cell Institute, Chemrar and the Consultation Centre for Cancer, signed the agreements with Heber Biotec, which is the holder of the exclusive trade rights of the products and projects of the Centre for Genetic Engineering and Biotechnology (CIGB).
About the agreements, the president of Heber Biotec, Eulogio Pimentel, said that this constitutes a turning point for Cuban biotechnology.
The Vice President of the Skolkovo Foundation, Alexander Chernov, said that the signing of these documents represents the very high level of cooperation reached by both sides.
‘The agreements we have signed are very pragmatic. This is collaboration work, strong, hard and productive work”.
These agreements will allow the pharmaceutical cooperation in the area of patents and licenses, as well as the exchange of specialists, he said.
He also said that these agreements will allow the Russian side to reach Latin American markets through Cuba and, at the same time, will allow that the Cuban products reach the European market through Russia, he added.Tags: Alexander Chernov, CIGB - Centre for Genetic Engineering and Biotechnology, Cuba and Russia Biomedical Cooperation Agreement, Cuba IP, Cuban biotechnology, Eulogio Pimentel, Hebe Biotec, Latin America IP, Russia IP, Skolkovo Foundation